Table S3.

Effect of others factor (than age), on lost to follow-up in the first 36 months after ART initiation (Cox models), for patients >60 years while starting ART

Variables	Number of lost to follow-up	Univariable models		Multivariable models
		HR (95% CI)	P-value	HR (95% CI)	P-value
Gender			0.74
Female	273	1
Male	273	1.03 (0.87–1.22)
Year of ART initiation			0.001		<0.0001
<2007	117	1		1
2007–2010	173	0.98 (0.78–1.24)		1.00 (0.78–1.27)
2011 and after	256	1.36 (1.09–1.70)		1.65 (1.30–2.11)
Initial clinical stage			<0.0001		0.0024
A,B/I,II	153	1		1
AIDS/III,IV	184	1.38 (1.11–1.71)		1.41 (1.13–1.76)
Missing	209	1.63 (1.32–2.00)		1.41 (1.13–1.77)
Initial CD4 cell count (cells/µL)			<0.0001		0.0025
≥350	69	1		1
200–349	88	0.75 (0.54–1.02)		0.80 (0.58–1.10)
100–199	110	0.96 (0.71–1.30)		0.94 (0.69–1.29)
50–99	53	1.25 (0.88–1.79)		1.26 (0.87–1.82)
0–49	79	1.57 (1.14–2.17)		1.49 (1.06–2.08)
Missing	147	1.31 (0.99–1.75)		1.05 (0.78–1.43)
Initial hemoglobin (g/dL)			<0.0001		0.0021
≥12	34	1		1
10–12	76	1.48 (0.99–2.22)		1.49 (0.99–2.24)
7.5–10	71	1.80 (1.20–2.71)		1.61 (1.06–2.45)
<7.5	8	1.45 (0.67–3.14)		1.32 (0.61–2.90)
Missing	357	2.33 (1.64–3.32)		2.04 (1.40–2.97)
First ART regimen			<0.0001		0.029
AZT+3TC/FTC + NVP/EFV	159	1		1
D4T+3TC/FTC + NVP/EFV	91	0.95 (0.74–1.23)		1.05 (0.79–1.38)
TDF+3TC/FTC + NVP/EFV	91	1.23 (0.95–1.59)		1.08 (0.83–1.42)
Others/unknown	205	1.71 (1.39–2.11)		1.39 (1.10–1.74)
BMI (kg/m2)			<0.0001		<0.0001
18–25	119	1		1
<18	56	1.48 (1.08–2.03)		1.30 (0.94–1.80)
≥25	32	0.86 (0.58–1.27)		0.88 (0.59–1.31)
Missing	339	1.89 (1.54–2.34)		1.95 (1.54–2.47)
Total number of patients started ART in 2014–2015 and still in care, in the facility			0.0004		<0.0001
<500	161	1		1
500–1000	264	0.73 (0.60–0.88)		0.96 (0.77–1.19)
≥1000	121	0.64 (0.51–0.82)		0.56 (0.43–0.73)

Abbreviations: ART, antiretroviral therapy; BMI, body mass index.